Literature DB >> 25712375

Effect of cancer-associated fibroblasts on the migration of glioma cells in vitro.

Jana Trylcova1, Petr Busek, Karel Smetana, Eva Balaziova, Barbora Dvorankova, Alzbeta Mifkova, Aleksi Sedo.   

Abstract

Cancer-associated fibroblasts (CAFs) significantly influence biological properties of many tumors. The role of these mesenchymal cells is also anticipated in human gliomas. To evaluate the putative role of CAFs in glioblastoma, we tested the effect of CAF conditioned media on the proliferation and chemotaxis of glioma cells. The proliferation of glioma cells was stimulated to similar extent by both the normal fibroblasts (NFs) and CAF-conditioned media. Nevertheless, CAF-conditioned media enhanced the chemotactic migration of glioma cells significantly more potently than the media from normal fibroblasts. In order to determine whether CAF-like cells are present in human glioblastomas, immunofluorescence staining was performed on tissue samples from 20 patients using markers typical for CAFs. This analysis revealed regular presence of mesenchymal cells expressing characteristic CAF markers α-smooth muscle actin and TE-7 in human glioblastomas. These observations indicate the potential role of CAF-like cells in glioblastoma biology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25712375     DOI: 10.1007/s13277-015-3259-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.

Authors:  Petr Busek; Jarmila Stremenova; Lucie Sromova; Marek Hilser; Eva Balaziova; Dalibor Kosek; Jana Trylcova; Hynek Strnad; Evzen Krepela; Aleksi Sedo
Journal:  Int J Biochem Cell Biol       Date:  2012-01-28       Impact factor: 5.085

Review 2.  Tumor microenvironment: the role of the tumor stroma in cancer.

Authors:  Hanchen Li; Xueli Fan; Jeanmarie Houghton
Journal:  J Cell Biochem       Date:  2007-07-01       Impact factor: 4.429

3.  Identification of potential pluripotency determinants for human embryonic stem cells following proteomic analysis of human and mouse fibroblast conditioned media.

Authors:  Andrew B J Prowse; Leon R McQuade; Katherine J Bryant; Helder Marcal; Peter P Gray
Journal:  J Proteome Res       Date:  2007-07-27       Impact factor: 4.466

4.  Cancer associated fibroblasts: the dark side of the coin.

Authors:  Paolo Cirri; Paola Chiarugi
Journal:  Am J Cancer Res       Date:  2011-03-12       Impact factor: 6.166

5.  Synthetic polyamine BPA-C8 inhibits TGF-β1-mediated conversion of human dermal fibroblast to myofibroblasts and establishment of galectin-1-rich extracellular matrix in vitro.

Authors:  Alžběta Mifková; Ondřej Kodet; Pavol Szabo; Jan Kučera; Barbora Dvořánková; Sabine André; Girish Koripelly; Hans-Joachim Gabius; Jean-Marie Lehn; Karel Smetana
Journal:  Chembiochem       Date:  2014-05-27       Impact factor: 3.164

6.  Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study.

Authors:  P Wesseling; R O Schlingemann; F J Rietveld; M Link; P C Burger; D J Ruiter
Journal:  J Neuropathol Exp Neurol       Date:  1995-05       Impact factor: 3.685

7.  Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.

Authors:  Anne Clavreul; Catherine Guette; Rogatien Faguer; Clément Tétaud; Alice Boissard; Laurent Lemaire; Audrey Rousseau; Tony Avril; Cécile Henry; Olivier Coqueret; Philippe Menei
Journal:  J Pathol       Date:  2014-02-20       Impact factor: 7.996

Review 8.  Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.

Authors:  Luca Persano; Elena Rampazzo; Giuseppe Basso; Giampietro Viola
Journal:  Biochem Pharmacol       Date:  2012-10-11       Impact factor: 5.858

9.  The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment.

Authors:  Alina Filatova; Till Acker; Boyan K Garvalov
Journal:  Biochim Biophys Acta       Date:  2012-10-16

10.  Upregulation of IL-6, IL-8 and CXCL-1 production in dermal fibroblasts by normal/malignant epithelial cells in vitro: Immunohistochemical and transcriptomic analyses.

Authors:  Michal Kolář; Pavol Szabo; Barbora Dvořánková; Lukáš Lacina; Hans-Joachim Gabius; Hynek Strnad; Jana Sáchová; Cestmír Vlček; Jan Plzák; Martin Chovanec; Zdeněk Cada; Jan Betka; Zdeněk Fík; Jan Pačes; Hana Kovářová; Jan Motlík; Karla Jarkovská; Karel Smetana
Journal:  Biol Cell       Date:  2012-12       Impact factor: 4.458

View more
  21 in total

1.  Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness.

Authors:  Njainday Pulo Jobe; Daniel Rösel; Barbora Dvořánková; Ondřej Kodet; Lukáš Lacina; Rosana Mateu; Karel Smetana; Jan Brábek
Journal:  Histochem Cell Biol       Date:  2016-04-21       Impact factor: 4.304

2.  Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.

Authors:  Petr Busek; Eva Balaziova; Ivana Matrasova; Marek Hilser; Robert Tomas; Martin Syrucek; Zuzana Zemanova; Evzen Krepela; Jaromir Belacek; Aleksi Sedo
Journal:  Tumour Biol       Date:  2016-08-04

Review 3.  Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

Authors:  Leonardo B de Paula; Fernando L Primo; Antonio C Tedesco
Journal:  Biophys Rev       Date:  2017-08-19

4.  Fibroblasts potentiate melanoma cells in vitro invasiveness induced by UV-irradiated keratinocytes.

Authors:  Njainday Pulo Jobe; Veronika Živicová; Alžběta Mifková; Daniel Rösel; Barbora Dvořánková; Ondřej Kodet; Hynek Strnad; Michal Kolář; Aleksi Šedo; Karel Smetana; Karolina Strnadová; Jan Brábek; Lukáš Lacina
Journal:  Histochem Cell Biol       Date:  2018-02-12       Impact factor: 4.304

Review 5.  Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.

Authors:  Mihaela Aldea; Ioan Alexandru Florian; Gabriel Kacso; Lucian Craciun; Sanda Boca; Olga Soritau; Ioan Stefan Florian
Journal:  Pharm Res       Date:  2016-05-26       Impact factor: 4.200

Review 6.  Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.

Authors:  Zhaoshi Bao; Yongzhi Wang; Qiangwei Wang; Shengyu Fang; Xia Shan; Jiguang Wang; Tao Jiang
Journal:  Front Med       Date:  2021-04-24       Impact factor: 4.592

7.  Stromal expression of Fer suppresses tumor progression in renal cell carcinoma and is a predictor of survival.

Authors:  Kensuke Mitsunari; Yasuyoshi Miyata; Shin-Ichi Watanabe; Akihiro Asai; Takuji Yasuda; Shigeru Kanda; Hideki Sakai
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

Review 8.  Intercellular crosstalk in human malignant melanoma.

Authors:  Barbora Dvořánková; Pavol Szabo; Ondřej Kodet; Hynek Strnad; Michal Kolář; Lukáš Lacina; Eliška Krejčí; Ondřej Naňka; Aleksi Šedo; Karel Smetana
Journal:  Protoplasma       Date:  2016-11-03       Impact factor: 3.356

9.  Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Authors:  Yaoqing Shen; Cameron J Grisdale; Sumaiya A Islam; Pinaki Bose; Jake Lever; Eric Y Zhao; Natalie Grinshtein; Yussanne Ma; Andrew J Mungall; Richard A Moore; Xueqing Lun; Donna L Senger; Stephen M Robbins; Alice Yijun Wang; Julia L MacIsaac; Michael S Kobor; H Artee Luchman; Samuel Weiss; Jennifer A Chan; Michael D Blough; David R Kaplan; J Gregory Cairncross; Marco A Marra; Steven J M Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-30       Impact factor: 11.205

10.  IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.

Authors:  Manuel Röhrich; Anastasia Loktev; Annika K Wefers; Annette Altmann; Daniel Paech; Sebastian Adeberg; Paul Windisch; Thomas Hielscher; Paul Flechsig; Ralf Floca; Dominik Leitz; Julius P Schuster; Peter E Huber; Jürgen Debus; Andreas von Deimling; Thomas Lindner; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.